Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) stock jumped 5.68% on Friday to $224.05 against a previous-day closing price of $212.01. With 3.41 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.93 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $226.00 whereas the lowest price it dropped to was $188.88. The 52-week range on ALNY shows that it touched its highest point at $220.92 and its lowest point at $117.58 during that stretch. It currently has a 1-year price target of $203.86. Beta for the stock currently stands at 0.76.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ALNY was up-trending over the past week, with a rise of 56.11%, but this was up by 49.37% over a month. Three-month performance surged to 56.21% while six-month performance rose 54.24%. The stock gained 22.14% in the past year, while it has gained 32.12% so far this year. A look at the trailing 12-month EPS for ALNY yields -8.16 with Next year EPS estimates of -4.11. For the next quarter, that number is -1.81. This implies an EPS growth rate of 3.50% for this year and 49.90% for next year. EPS is expected to grow by 7.86% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -8.50%.
Float and Shares Shorts:
At present, 120.90 million ALNY shares are outstanding with a float of 119.80 million shares on hand for trading. On Jul 14, 2022, short shares totaled 4.99 million, which was 4.13% higher than short shares on Jun 14, 2022. In addition to ALNY as the firm’s Alnylam Pharmaceuticals, Inc., ALNA serves as its Allena Pharmaceuticals, Inc.
Through their ownership of 99.25% of ALNY’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 67.05% of ALNY, in contrast to 28.47% held by mutual funds. Shares owned by individuals account for 18.39%. As the largest shareholder in ALNY with 12.86% of the stake, Fidelity Management & Research Co holds 15,536,134 shares worth 15,536,134. A second-largest stockholder of ALNY, The Vanguard Group, Inc., holds 10,581,970 shares, controlling over 8.76% of the firm’s shares. Baillie Gifford & Co. is the third largest shareholder in ALNY, holding 10,139,729 shares or 8.39% stake. With a 4.57% stake in ALNY, the American Funds Growth Fund of Ame is the largest stakeholder. A total of 5,514,960 shares are owned by the mutual fund manager. The Vanguard Health Care Fund, which owns about 4.29% of ALNY stock, is the second-largest Mutual Fund holder. It holds 5,187,603 shares valued at 756.61 million. Vanguard Total Stock Market Index holds 2.95% of the stake in ALNY, owning 3,565,094 shares worth 519.97 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ALNY since 26 analysts follow the stock currently. There are 15 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 9 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 1 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ALNY analysts setting a high price target of $430.00 and a low target of $135.00, the average target price over the next 12 months is $225.57. Based on these targets, ALNY could surge 91.92% to reach the target high and fall by -39.75% to reach the target low. Reaching the average price target will result in a growth of 0.68% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ALNY will report FY 2022 earnings on 02/09/2023. Analysts have provided yearly estimates in a range of -$4.47 being high and -$9.41 being low. For ALNY, this leads to a yearly average estimate of -$7.32. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Alnylam Pharmaceuticals Inc. surprised analysts by -$0.69 when it reported -$2.29 EPS against a consensus estimate of -$1.60. The surprise factor in the prior quarter was -$0.19. Based on analyst estimates, the high estimate for the next quarter is -$1.02 and the low estimate is -$2.33. The average estimate for the next quarter is thus -$1.74.
Summary of Insider Activity:
Insiders traded ALNY stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 1,754 shares were sold. The number of buy transactions has increased to 17 while that of sell transactions has risen to 52 over the past year. The total number of shares bought during that period was 222,249 while 204,718 shares were sold.